Navigation Links
U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
Date:12/16/2010

regnancy – often before a woman finds out she is pregnant.  As a result, daily folate supplementation is particularly important at least one month before and three months after conception.(2)

"Combining an oral contraceptive with folate is important, because women may become pregnant during OC use or shortly after discontinuation, possibly before seeking preconception counseling from their healthcare providers," said Dr. Anita Nelson, Professor of Obstetrics and Gynecology at the Harbor-UCLA Medical Center, Torrance, California.  "For women who already use YASMIN for contraception, SAFYRAL offers these women a new option to receive daily folate supplementation as part of their OC routine."

Women should not use SAFYRAL if they smoke and are over age 35.  Smoking increases the risk of serious side effects from the Pill, which can be life-threatening, including blood clots, stroke or heart attack.  This risk increases with age and number of cigarettes smoked.

Patients are advised to alert their healthcare provider if they are taking folate supplements.  SAFYRAL is not indicated during pregnancy.  SAFYRAL has 99 percent contraceptive efficacy when used as directed.  If pregnancy occurs during treatment with SAFYRAL, further intake must be stopped.  If a woman discontinues use of SAFYRAL either with the intention of becoming pregnant or if she discontinues due to pregnancy while on the product, she is strongly encouraged to speak with her healthcare provider about taking a multivitamin with folic acid or another folate to maintain recommended folate intake.

SAFYRAL is in a 21/7 day regimen consisting of 21 days of drospirenone 3 mg/ethinyl estradiol 30 mcg with levomefolate calcium 451 mcg (Metafolin®*) followed by seven days of Metafolin only.  SAFYRAL is expected to be available in mid-January 2011 by prescription only.

Women should not use SAFYRAL if they have kidney, liver, or
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
2. FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment
3. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
4. FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury
5. FDA Approves New Treatment Option for Late-Stage Breast Cancer
6. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
7. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
8. FDA Approves New Indication for Afinitor
9. FDA Approves Teflaro for Bacterial Infections
10. FDA Approves Latuda to Treat Schizophrenia in Adults
11. FDA Approves Additional Medical Indication for Sprycel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 17 Innocoll, Inc., a privately-held,biopharmaceutical company, ... phase,2 clinical trials sponsored by its wholly ... GENTAMICIN TOPICAL for the,treatment and prevention of ... GENTAMICIN TOPICAL is a biodegradable and fully ...
... Biosciences,Incorporated (Nasdaq: KOSN ) presented preclinical data ... in vitro and in vivo,activity as well as ... NEI anticancer mechanism of action correlating inhibition,of the ... cancer cells,compared to normal cells. Data on Kosan,s ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:4/23/2014)... research, published in the journal Oncotarget , ... different appearances or their own DNA signatures within ... difficult to design effective, targeted treatment strategies. , ... EGFR mutation and either the KRAS or BRAF ... by the EGFR gene mutation have that specific ...
(Date:4/22/2014)... is a popular high school sport in the United ... study by researchers in the Center for Injury Research ... to compare and describe the occurrence and distribution patterns ... high school athletic training setting among adolescents and teens. ... of Athletic Training , examined data relating to adolescents ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
(Date:4/22/2014)... is available in German . ... intracellular signaling molecules, but their mode of action is ... cellular function and behavior, while at high concentrations they ... DNA. To analyze how redox signaling unfolds in single ... technique has been developed jointly by the teams of ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Neuroimaging: Live from inside the cell 2
... FairWarning, Inc. a provider of healthcare privacy auditing ... titled Addressing Electronic Health Record Privacy ... The Webinar will feature John Wade, ... Robert Sullivan of PricewaterhouseCoopers, Healthcare Advisory ...
... Tour Shows Dramatic Impact of AIDS on Children, ... Funds for Social Causes, CINCINNATI, Feb. 13 ... Network (TPN), has partnered with World,Vision to produce ... a national tour designed to raise awareness about ...
... Monitoring Committee holds third meeting -, ... Life Sciences,Inc. (TSX: BNC), a research-based, technology-driven ... update on the progress,of its North American ... - trademarked Urocidin - in patients with ...
... Most Fertile ... Throughout Entire Month, PRINCETON, N.J., Feb. 13 Trying to predict ... provide,only a handful of chances to identify the two most fertile days ... most fertile,days: The new FIRST RESPONSE Daily Ovulation Test includes 20 testing,sticks ...
... for heart, pneumonia care, ST. PAUL, Minn., Feb. ... metro area in three key areas of a,national quality ... heart attack, heart failure and pneumonia care, according to,The ... "We,re very proud of the ongoing quality improvement work ...
... GARDENA, Calif., Feb. 13 Consumers today are ... away from,carbs, while other experts say that the ... we take in each day. The answers may ... oldest populations on earth, namely,Japan., Zojirushi ( ...
Cached Medicine News:Health News:FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges 2Health News:The Brand Experience Teams With World Vision to Launch 'Experience: AIDS' Multi-Media Exhibit 2Health News:The Brand Experience Teams With World Vision to Launch 'Experience: AIDS' Multi-Media Exhibit 3Health News:Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM) 2Health News:Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM) 3Health News:New FIRST RESPONSE(R) Home Ovulation Test Takes the Guesswork Out of Conception 2Health News:Busting the Myth, One Bowl at a Time 2
The C-Reactive Protein (CRP) assay is used for the quantitative analysis of C-reactive protein in human serum and plasma. Kit is for use with the Abbot Laboratories Aeroset, ARCHITECT c8000 or ARCHI...
... illuminating the way for faster, easier, and ... QCount™ utilizes the latest digital FireWire technology, ... sample images. Its ease of use allows ... This extraordinary time reduction frees technicians to ...
... Traditionally, when choosing a non-contact diagnostic lens, ... wide field of view and high magnification. ... introduced by Volk Optical, doctors can have both ... widest field of view available in a non-contact ...
... XCEL Suture Anchor is a 3.0mm single ... Acid (PLLA). The anchor barb catches on ... inserter until it "breaks" free. The small ... it also frequently used in rotator cuff ...
Medicine Products: